GILD/ABBV/ENTA/MRK—What doesn’t the US like about V-Pak?
GT1 prevalence in the US is about 2/3 GT1a, where Viekira requires the use of ribavirin, crimping market share.
In Japan and major European countries, GT1 prevalence is about 2/3 GT1b. This benefits Viekira (compared to the US market) because Viekira does not require ribavirin for GT1b patients unless they have cirrhosis.
Market Data 
Markets 
AI
